Stock Performance and Market Context
On 19 Feb 2026, Lasa Supergenerics Ltd recorded its lowest price in the past year at Rs.7.7, a level not seen before in its trading history. This new low comes after the stock has declined for four consecutive sessions, resulting in a cumulative loss of 9.76% over this period. The stock’s day change was a negative 2.91%, underperforming the Pharmaceuticals & Biotechnology sector by 3.87% on the same day.
Technical indicators show the stock trading below all key moving averages, including the 5-day, 20-day, 50-day, 100-day, and 200-day averages, signalling a persistent bearish momentum. This contrasts with the broader market, where the Sensex, despite a sharp reversal from an initial positive opening, remains only 3.29% below its 52-week high of 86,159.02. The Sensex closed at 83,411.80, down 0.39% on the day, and while it trades below its 50-day moving average, the 50DMA remains above the 200DMA, indicating a generally positive medium-term trend for the benchmark.
Financial Performance and Profitability Concerns
Lasa Supergenerics Ltd’s financial results have shown considerable strain. The company reported net sales of Rs.5.26 crores over the latest six-month period, representing a steep decline of 92.74% compared to previous periods. This sharp contraction in revenue has been accompanied by a net loss after tax (PAT) of Rs.-2.55 crores in the most recent quarter, a fall of 17.3% year-on-year.
The company’s profitability metrics further highlight challenges. The average Return on Equity (ROE) stands at a modest 3.54%, indicating limited profitability generated from shareholders’ funds. Additionally, the EBIT to interest coverage ratio averages at -5.16, underscoring difficulties in servicing debt obligations effectively. These figures contribute to the company’s current Mojo Grade of Strong Sell, an upgrade from the previous Sell rating as of 11 Feb 2025, reflecting deteriorated fundamentals and increased risk.
Fundamentals that don't lie! This Small Cap from Trading shows consistent growth and price strength over time. A reliable pick you can truly count on.
- - Strong fundamental track record
- - Consistent growth trajectory
- - Reliable price strength
Valuation and Risk Profile
The stock’s valuation metrics indicate elevated risk levels. Despite a 63.87% decline in stock price over the past year, the company’s profits have reportedly increased by 101.8%, resulting in a Price/Earnings to Growth (PEG) ratio of 1.5. This disparity suggests that the market is pricing in significant concerns beyond earnings growth, possibly related to the company’s weak fundamentals and financial health.
Moreover, Lasa Supergenerics Ltd has consistently underperformed the BSE500 benchmark over the last three annual periods, reinforcing a pattern of relative weakness. The stock’s 52-week high was Rs.24.6, highlighting the extent of the recent decline and the challenges faced in regaining investor confidence.
Shareholding and Sector Position
The company remains majority-owned by promoters, maintaining a concentrated shareholding structure. Operating within the Pharmaceuticals & Biotechnology sector, Lasa Supergenerics Ltd faces competitive pressures alongside sectoral dynamics. While the broader sector has shown resilience, the company’s individual performance metrics have lagged behind peers, as reflected in its Mojo Score of 3.0 and the Strong Sell grade.
Holding Lasa Supergenerics Ltd from Pharmaceuticals & Biotechnology? See if there's a smarter choice! SwitchER compares it with peers and suggests superior options across market caps and sectors!
- - Peer comparison ready
- - Superior options identified
- - Cross market-cap analysis
Summary of Key Metrics
To summarise, Lasa Supergenerics Ltd’s stock has reached a new 52-week low of Rs.7.7, reflecting a sustained decline over recent sessions and a year-long underperformance of 63.87%. The company’s financial indicators reveal significant revenue contraction, net losses, and limited profitability, with an average ROE of 3.54% and a negative EBIT to interest coverage ratio. The stock trades below all major moving averages, signalling continued bearish momentum. Despite the broader market’s relative strength, Lasa Supergenerics Ltd’s fundamentals and valuation metrics have led to a Strong Sell rating and a Mojo Score of 3.0, underscoring the challenges it currently faces within the Pharmaceuticals & Biotechnology sector.
Limited Period Only. Start at Rs. 9,999 - Get MojoOne for 1 Year + 3 Months FREE (60% Off) Get 71% Off →
